Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

被引：4
|
作者：
Planchard, D. [1 ]
Brahmer, J. R. [2 ]
Yang, J. C-H. [3 ]
Kim, H. R. [4 ]
Li, R. K. [5 ]
Han, J-Y. [6 ]
Cortinovis, D. L. [7 ]
Runglodvatana, Y. [8 ]
Nakajima, E. [9 ]
Ragone, A. [10 ]
Winter, M. [11 ]
Gustavson, M. [12 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Johns Hopkins Kimmel Canc Ctr, Thorac Oncol Program, Baltimore, MD USA
[3] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[4] Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med, Seoul, South Korea
[5] St Lukes Med Ctr Quezon City, Dept Med Oncol, Quezon City, Philippines
[6] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea
[7] Fondazione IRCCS San Gerardo dei Tintori, SC Oncol Med, Monza, Italy
[8] Navamindradhiraj Univ, Div Med Oncol, Vajira Hosp, Fac Med, Bangkok, Thailand
[9] AstraZeneca, Late Dev Oncol, R&D, Gaithersburg, MD USA
[10] AstraZe neca, Late Dev Oncol, R&D, Mississauga, ON, Canada
[11] AstraZeneca, Data Sci & Quantitat Biol, Cambridge, England
[12] AstraZeneca, Translat Med, Oncol R&D, Gaithersburg, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1507TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 2, Randomized, Open-Label Study of Ramucirumab in Combination With First-Line Pemetrexed and Platinum Chemotherapy in Patients With Nonsquamous, Advanced/Metastatic Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Spigel, David
    Tehfe, Mustapha
    Thomas, Sachdev
    Reck, Martin
    Verma, Sunil
    Eakle, Janice
    Bustin, Frederique
    Goldschmidt, Jerome, Jr.
    Cao, Dachuang
    Alexandris, Ekaterine
    Yurasov, Sergey
    Camidge, D. Ross
    Bonomi, Philip
    CANCER, 2015, 121 (06) : 883 - 892
  • [32] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
    Hall, Richard Delmar
    Gadgeel, Shirish M.
    Garon, Edward B.
    Bria, Emilio
    Reck, Martin
    Vida, John
    Zhou, Honghong
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] BEPACT lung: A prospective, multicenter, non-interventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)
    Sibille, A.
    Bustin, F.
    Compere, C.
    Cuppens, K.
    Coulon, S. H.
    Decoster, L.
    Decoster, L.
    Demedts, I.
    Deschepper, K.
    Janssens, A.
    Ocak, S.
    Oyen, C.
    Pat, K. E.
    Pieters, T.
    Pruniau, V.
    Vansteenkiste, J. F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S790 - S791
  • [35] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [36] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Hidehito Horinouchi
    Noboru Yamamoto
    Hiroshi Nokihara
    Takeshi Horai
    Makoto Nishio
    Fumiyoshi Ohyanagi
    Atsushi Horiike
    Kazuhiko Nakagawa
    Masaaki Terashima
    Takafumi Okabe
    Hiroyasu Kaneda
    Mark D. McKee
    Dawn M. Carlson
    Hao Xiong
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 37 - 43
  • [37] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Horai, Takeshi
    Nishio, Makoto
    Ohyanagi, Fumiyoshi
    Horiike, Atsushi
    Nakagawa, Kazuhiko
    Terashima, Masaaki
    Okabe, Takafumi
    Kaneda, Hiroyasu
    McKee, Mark D.
    Carlson, Dawn M.
    Xiong, Hao
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 37 - 43
  • [38] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
    Andric, Z. G.
    Galffy, G.
    Cobo Dols, M.
    Szima, B.
    Stojanovic, G.
    Petrovic, M. D.
    Felip Font, E.
    Vicente Baz, D.
    Ponce Aix, S.
    Juan-Vidal, O.
    Tehenes, S.
    Szalai, Z.
    Losonczy, G.
    Calles Blanco, A.
    Bernabe, R.
    Duecker, K.
    Zhou, D.
    Schroeder, A.
    Guezel, G.
    Ciardiello, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
  • [39] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
    Raghav, Kanwal Pratap Singh
    Siena, Salvatore
    Takashima, Atsuo
    Kato, Takeshi
    Van den Eynde, Marc
    Di Bartolomeo, Maria
    Komatsu, Yoshito
    Kawakami, Hisato
    Peeters, Marc
    Andre, Thierry
    Lonardi, Sara
    Yamaguchi, Kensei
    Tie, Jeanne
    Castro, Cristina Gravalos
    Strickler, John H.
    Barrios, Daniel
    Yan, Qi
    Kamio, Takahiro
    Kobayashi, Kojiro
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345